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Florence Niel, 1 Michel Vidaud, 2 3 Service de Cytogénétique, Hô pital de Hautepierre, 67098 Strasbourg, France; * these authors contributed equally to this work and should both be considered first authors; † author for correspondence: fax 33-1-4981-2842, e-mail girodon@im3.inserm.fr) Cystic fibrosis (CF; MIM No. 219700), the most common autosomal recessive disease in Caucasians (1 ) , is caused by mutations in the gene encoding CF transmembrane conductance regulator (CFTR; MIM No. 602421) (2 ) . The disease may be revealed by fetal bowel hyperechogenicity during routine ultrasonography in the second trimester of pregnancy, even when there is no family history of CF. However, fetal bowel hyperechogenicity is not specific for CF: when found at this stage of pregnancy, it corresponds to CF in 2-20% of cases (1, (3) (4) (5) . Diagnostic investigations are based on screening for CF-causing mutations, fetal karyotyping, and screening for infections. Normal intestinal enzyme activities in amniotic fluid before 18 weeks of gestation reasonably rules out CF (6 ) . However, most women are referred after this time, and it is necessary to screen for CF mutations in the parents and, if possible, fetus. To date, almost 900 mutations have been described throughout the CFTR gene, but very few deletions have been identified (7 ) . Indeed, large deletions are not routinely screened for, given their rarity and the lack of suitable diagnostic tools. Conventional PCR-based methods usually detect deletions only when they are present in the homozygous state. As a result, the frequency of CFTR deletions is underestimated. Two relatively frequent large deletions have recently been described: 3120ϩ1kbdel8.6kb was found in 13% of CF chromosomes in Israeli-Arab patients (8 ) , and CFTRdele2,3 accounts for 1-6.4% of CF chromosomes in Slavic populations (9 ) .
A couple was referred to our laboratory for fetal hyperechogenic bowel diagnosed during a routine ultrasound scan at 20 weeks of gestation. The couple, who were first cousins of Turkish extraction, had no family history of CF. Diagnostic investigations were requested after genetic counseling, with the couple's informed consent. The fetal karyotype (amniotic cells) was normal, as were intestinal fetal enzyme activities.
Screening with an oligonucleotide ligation assay (CF-OLA; PE Biosystems) for 31 CF mutations frequently found among Caucasians showed a normal pattern in the parents, as in the control, whereas 3 of the 29 expected peaks were missing in the fetus (Fig. 1A) . Because these three peaks corresponded to two different PCR products spanning exon 19 of the CFTR gene, a deletion spanning exon 19 was suspected at the homozygous site in the fetus, rather than a mutation in the region recognized by either the PCR-OLA primers or a CF-OLA probe, that prevented ligation of the labeled products. Southern blotting was not suitable in this emergency situation to confirm the deletion. In addition, not enough fetal DNA was available, and in heterozygotes (the parents), only the detection of a new junction fragment on Southern blot can point to a gene rearrangement. Indeed, determination of the gene copy number after hybridization to CFTR cDNA is hazardous because the intensity of hybridization signals may vary with exon length.
To firmly confirm the deletion and to rapidly establish the prenatal diagnosis of CF, we used fluorescent TaqMan TM -based kinetic quantitative PCR on an ABI Prism TM 7700 Sequence Detection System (PE Biosystems). We determined the relative copy numbers of CFTR exon 19 and the albumin gene (ALB), which served as a reference internal control in each single reaction (10 ) , in DNA from amniocytes, and from white blood cells of the parents and a control. The copy number of exon 19 was twofold lower in each parent's DNA than in the control DNA and was near zero in the fetal DNA, confirming the presence of a deletion and strongly suggesting CF in the fetus (Table 1) . However, given the late stage of gestation, the parents decided to continue the pregnancy, and a girl was delivered at term. The meconium was emitted spontaneously but was thick. The diagnosis of CF was confirmed at 6 weeks of life by a positive sweat test.
The deletion was restricted to exon 19; PCR products were obtained in the fetus from exon 18 (not shown) and a fragment of intron 19, including the site of the 3849ϩ10kbC3 T mutation (peak 16 in Fig. 1A ). To identify the two breakpoints between exons 18 and 20, several long-range PCR experiments were performed on genomic DNA from cultured placental cells obtained after birth, using two forward primers located in intron 18 and two reverse primers located in intron 19, all designed from the sequence of human BAC clone 133K23 (GenBank Accession No. AC000061). The expected PCR product obtained from control DNAs was 7762 bp long, whereas an additional 2483-bp fragment was obtained with the parents' DNA, corresponding to a 5279-bp deletion. Only the small fragment was observed in placental DNA.
Direct sequencing of this product identified the deletion breakpoints. The deletion, starting 15 kb after the last nucleotide of exon 18 and spanning 5279 bp, was designated 3600ϩ15kbdel5.3kb, or CFTRdele19. The resulting putative CFTR protein presumably lacks 83 amino acids and, thus, part of the second nucleotide-binding domain (NBD2), which is involved in CFTR gating by adenosine triphosphate hydrolysis (11 ) and appears critical for CFTR function. This deletion could be the consequence of Fig. 1B) . Similarly, such a short motif has been found at the breakpoints of two other CFTR gene deletions (8, 9 ) .
We designed a duplex-PCR experiment to detect, in a single step, both the wild-type and the deleted alleles, and to determine the frequency of the deletion in 116 CF patients of various origins in whom one or two mutations remained to be identified (total of 161 CF chromosomes, including 6 from Turkish patients). Forty PCR cycles were run with primer annealing at 55°C and 0.2 mol/L each primer. Primers 5ЈCFdel19 (5Ј-TACTTGAGGATAGAAC-CAGGAT-3Ј) and 3ЈCFdel19 (5Ј-GCAAATGAAGGTCT-GTGAAACT-3Ј), which flank the deletion breakpoints, yielded a 248-bp fragment in the presence of the deletion, whereas control primers 5ЈCF19 (5Ј-GTGAAATTGTCT-GCCATTCTT-3Ј) and 3ЈCF19 (5Ј-AGGCTACTGGGAT-TCACTTA-3Ј) amplified a 407-bp fragment that included exon 19. This assay precisely identifies the 3600ϩ 15kbdel5.3kb mutation and may be more applicable than long-range PCR in routine laboratories. No other CFTRdele19 alleles were found in the 161 CF chromosomes tested. The deletion should therefore be screened for in a wider population, especially in Turkish patients, to evaluate its frequency and, hence, the relevance of the molecular test. Nevertheless, prenatal diagnosis is now possible for the couple's future pregnancies, if requested, as well as carrier testing of the family.
This case illustrates the limitations of routinely used CFTR gene screening methods and the value of testing the fetus with hyperechogenic bowel even in the absence of a detectable mutation in the parents. The diagnosis of the deletion of exon 19 here was rapidly confirmed by realtime quantitative PCR, which demonstrated one-half the copy number of exon 19 in each parent compared with a control, and no copy in the fetus. To our knowledge, this is the first report of prenatal CF diagnosis ascertained by this approach.
Only eight large CFTR gene deletions that remove coding regions have been reported to date (7 ), probably because conventional PCR-based techniques are designed to detect point mutations and miss large deletions. In five cases, as in the case reported here, deletions were suspected after failure of conventional PCR amplification targeting particular exons because they were present in CF patients in the homozygous state. In two others, hemizygosity was suggested by the lack of heterozygosity for the ⌬F508 or Y1092X mutation in one parent of an apparently homozygous CF child (14, 15 ) . This underlines the need to study the family when CF patients appear homozygous for a mutation. Partial hemizygosity may in other cases be shown by segregation studies of CFTR intragenic microsatellites when the deletions encompass The mutations tested were S549N, S549R, R553X, G551D, V520F, ⌬I507, ⌬F508, Q493X, 1717-1G3 A, G542X, R560T, R347P, R347H, 3849ϩ4A3 G, W1282X, R334W, 1078delT, 3849ϩ10kbC3 T, R1162X, N1303K, 3659delC, 3905insT, A455E, R117H, Y122X, 2183AA3 G, 2789ϩ5G3 A, 1898ϩ1G3 A, 621ϩ1G3 T, 711ϩ1G3 T, and G85E. They show 29 (control; left) vs 26 (fetus; right) labeled ligation products generated from 31 pairs of specific oligonucleotides. The use of three different fluorescent dyes enabled the separation of ligation products having the same length. The three peaks absent in the fetus (arrows) are restricted to exon 19 and 5Ј intron 19 (peak 12, 3849ϩ4A3 G; peak 17, R1162X; peak 19, 3659delC). Data were obtained from an 8% polyacrylamide gel run in 8 mol/L urea. Ligation products were analyzed on an ABI Prism 377 instrument. (B), the nucleotide sequence surrounding the breakpoints is shown (middle strand; Del), along with the wild-type sequence located proximal (top strand, left; 3ЈIVS18) and distal (bottom strand, right; 5ЈIVS19). The identical sequences are shaded.
such polymorphic sites (16 ) , but this approach would have failed in the case reported here. Nasal epithelial CFTR transcript analysis may also point to a deletion, in the homozygous or heterozygous state, as in the case of the very recently described CFTRdele2,3 deletion (9 ).
Quantitative PCR on genomic DNA represents an interesting alternative to Southern blotting or pulse field gel electrophoresis for the diagnosis of deletions, especially in heterozygous patients who escape detection through routinely used PCR-based methods. This technique was recently shown to be particularly useful in ascertaining chromosome aneuploidy and gene amplification in cancers (10, 17 ) . Carrier screening for Duchenne and Becker muscular dystrophy and spinal muscular atrophy, in which deletions are frequent and for which quantitative assays have already been developed (18 -21 ) , should benefit from this technical improvement. However, large CFTR genomic deletions are quite rare in CF, although they are likely underestimated. No hot-spot or target site for deletions has been identified on the basis of the few deletions described to date. Therefore, several CFTR probes scattered throughout the gene would be necessary to screen for unknown CFTR gene deletions. Although this remains a technical challenge, the case reported here illustrates the interest to further develop a quantitative PCR-based approach for the diagnosis of unknown CFTR deletions, complementary to the detection of point defects. a For each DNA sample, four replicate experiments were performed, and the mean and SD were determined. The dose of CFTR gene is determined by dividing the average CFTR copy number by the average ALB copy number (CFTR/ALB) (17 ) .
b The probe and primer sequences for CFTR exon 19 were: forward primer, 5ЈCF19i (5Ј-CATACAAGAATGGCCAACTCTC-3Ј); reverse primer, 3ЈCF19i (5Ј-CACCTTCTGTGTATTTTGCTGTG-3Ј); probe, SQCF19 (5Ј-CTTTGACAGTCATTTGGCCCCCT-3Ј).
c The probe and primers sequences for the ALB gene were: forward primer, 5ЈALB (5Ј-GCTGTCATCTCTTGTGGGCTGT-3Ј); reverse primer, 3ЈALB (5Ј-ACTCATGGGAGCT-GCTGGTTC-3Ј); probe, SQALB (5Ј-CCTGTCATGCCCACACAAATCTCTCC-3Ј).
d This value may correspond to a subtle maternal combination.
